

# Understanding awareness and perceptions of Bruton's Tyrosine Kinase Inhibitors (BTKis) among Healthcare Practitioners (HCPs) in Europe and the United States

P1087

MSMilan2023 – 9th JointECTRIMS-ACRIMS Meeting | 11-13 October 2023

<sup>1</sup>Sandra Teoh, <sup>1</sup>Nazira Jainis, <sup>1</sup>Hasifullah Ibrahim, <sup>2</sup>Denise Baldock, <sup>2</sup>Simone Gabriele, <sup>3</sup>Joseph Vindici

<sup>1</sup>Ipsos, Kuala Lumpur, Malaysia, <sup>2</sup>Ipsos, London, United Kingdom, <sup>3</sup>Ipsos, New Jersey, US

## INTRODUCTION

Ongoing research of Bruton's Tyrosine Kinase Inhibitors (BTKis) shows distinct properties due to their unique non-depleting activity on B cells, specifically in selectively modulating only autoreactive B cells, reducing B-T-cell interactions and inflammatory responses, and suppressing pro-inflammatory microglia that allow them to target Multiple Sclerosis (MS) in a way that most other disease-modifying therapies (DMTs) cannot [1]. As such, the role BTKis could play in the progressive MS space is becoming of increasing focus [1,2].

## METHOD

The Ipsos MS Therapy Monitor, an ongoing multi-centre online survey of treating neurologists (MS nurses included in UK) was conducted in Q4 2021 and Q4 2022 across EU4 (FR, DE, IT ES), UK and US:

- The HCP Perceptual Questionnaire collected de-identified perceptions from 245 EU4+UK and 116 US HCPs in Q4 2021 (Oct – Dec) and 251 EU4+UK and 110 US HCPs in Q4 2022 (Oct – Dec).

### HCP inclusion criteria

Each HCP had to satisfy the following criteria:

- Spend at least 10% of their time working in MS
- See ≥15 MS pts/month [UK, FR, IT, ESP, US] or ≥30 MS pts/quarter [DE]
- Write ≥5 DMT prescriptions /month (neurologists only)
- Responsible for treatment decisions of their MS pts
- Experience in managing MS for a minimum of 3 years


## OBJECTIVE

To assess healthcare practitioner (HCP) awareness of BTKis in late developmental stage (specifically tolebrutinib, evobrutinib, fenebrutinib) for the treatment of MS, likelihood to use and ascertain attributes that HCPs associate BTKis with.

# Participating HCPs were increasingly aware of BTKis for the treatment of MS. However, they saw little class differentiation among specific BTKis.

## RESULTS


**Figure 1:** Average aided awareness (%) of BTKis (tolebrutinib, evobrutinib, fenebrutinib) among sampled HCPs



SOURCE: Ipsos MS Therapy Monitor (HCPs providing de-identified patient record data on RRMS, PPMS & SPMS patients seen in consultation & perceptions online). Data © Ipsos 2023, all rights reserved.

**Figure 2:** Attitude towards use of BTKis once they are launched and available for use, among sampled HCPs aware of the treatment class (Q4 2022 data)


Q: Which of the following statements best fits with your attitude towards the late-stage development MS products once they are launched and available for use?



SOURCE: Ipsos MS Therapy Monitor (HCPs providing de-identified patient record data on RRMS, PPMS & SPMS patients seen in consultation & perceptions online in Q4 2022). Data © Ipsos 2023, all rights reserved.

**Figure 3:** Association of BTKis with key attributes among sampled HCPs aware of the treatment class (Q4 2022 data)

Q: Given your knowledge and perception of the product profiles of the following late-stage development products, please tick all the statements that you associate with each of these drugs.



SOURCE: Ipsos MS Therapy Monitor (HCPs providing de-identified patient record data on RRMS, PPMS & SPMS patients seen in consultation & perceptions online in Q4 2022). Data © Ipsos 2023, all rights reserved.

**Figure 4:** % of averaged sampled HCPs aware of BTKis and stating no differentiating factors between tolebrutinib, evobrutinib and fenebrutinib

Q: For you personally, what do you think are the differentiating factors for tolebrutinib, evobrutinib and fenebrutinib?



Note: small base <30, so findings must be viewed qualitatively

SOURCE: Ipsos MS Therapy Monitor (HCPs providing de-identified patient record data on RRMS, PPMS & SPMS patients seen in consultation & perceptions online in Q4 2022). Data © Ipsos 2023, all rights reserved.

## CONCLUSIONS

In this study cohort, a notable proportion of sampled HCPs were aware of late developmental stage BTKis and interested in using them in their future prescribing. Further investigation using a comparator cohort is warranted, and to better understand how HCPs perceive the differentiation between the individual BTKis and their place in MS treatment.

## LIMITATIONS

Patient management practices reported in this study represent the practices of physicians participating in the study and may vary from those of non-participating physicians.

## DISCLOSURES

All authors are employees of Ipsos and have nothing to disclose.

## REFERENCES

- Garg, N., Padron, E. J., Rammohan, K. W. & Goodman, C. F. (2022) Bruton's Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis, 11(20), 6139. [Journal of Clinical Medicine]
- Evonuk, K. S., Wang, S., Mattie, J., Cracchiolo, C.J., Mager, R., Ferenčič, Z., Sprague, E., Carrier, B., Schofield, K., Martinez, E., Steward, Z., Petrosino, T., Johnson, G.A., Yusuf, I., Plaisted, W., Naiman, Z., Delp, T., Carter, L. & Marušić, S. (2023). Bruton's tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination, 11, 115. [Acta Neuropathologica Communications]

DOWNLOAD THIS POSTER & ABSTRACT



## CONTACT US:

therapymonitors@ipsos.com

www.ipsos.com



© Ipsos 2023, all rights reserved